Amlodipine And Olmesartan Medoxomil Tablet, Film Coated
Product Images NDC 65862-855

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Amlodipine And Olmesartan Medoxomil (NDC 65862-855). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figures 1 & 2 (Amlodipineolme Fig1)

Two graphs showing the probability of achieving blood pressure targets at Week 8 with LOCF. The left graph plots the probability of achieving systolic blood pressure (SBP) under 140 mmHg against baseline SBP (mmHg) for placebo, Amlodipine 10 mg, Olmesartan Medoxomil 40 mg, and Amlodipine and Olmesartan Medoxomil Tablets 10 mg/40 mg. The right graph shows the probability of achieving diastolic blood pressure (DBP) under 90 mmHg versus baseline DBP (mmHg) for the same treatments.*

FDA Label Image

Figures 3 & 4 (Amlodipineolme Fig2)

This image contains two line graphs comparing the probability of achieving blood pressure targets with different treatments. The left graph shows the probability of achieving systolic blood pressure (SBP) below 130 mmHg at week 8 with LOCF, plotted against baseline SBP, for placebo, amlodipine 10 mg, olmesartan medoxomil 40 mg, and amlodipine and olmesartan medoxomil tablets 10 mg/40 mg. The right graph shows the probability of achieving diastolic blood pressure (DBP) below 80 mmHg at week 8 with LOCF, plotted against baseline DBP, for the same treatments.*

FDA Label Image

Package Label-principal Display Panel (5 mg/20 mg (30 Tablet Bottle))

Label for Amlodipine and Olmesartan Medoxomil Tablets, USP 5 mg/20 mg by Aurobindo Pharma Limited. The film-coated tablets are in a 30 count package. The label states the tablet contains 6.95 mg amlodipine besylate (equivalent to 5 mg amlodipine) and 20 mg olmesartan medoxomil. Distributed by Aurobindo Pharma USA, Inc., made in India. Storage instructions and regulatory information also appear.*

FDA Label Image

Package Label-principal Display Panel (5 mg/40 mg (30 Tablet Bottle))

Label for Amlodipine and Olmesartan Medoxomil Tablets, USP 5 mg/40 mg, film-coated tablets in a 30-tablet package. The label includes dosage details, storage instructions, and distributor information for Aurobindo Pharma USA, Inc. A barcode and NDC number 65862-855-30 are also visible.*

FDA Label Image

Package Label-principal Display Panel (10 mg/20 mg (30 Tablet Bottle))

Label for Amlodipine and Olmesartan Medoxomil Tablets, USP 10 mg/20 mg film-coated tablets from Aurobindo Pharma USA, Inc. The label shows the product name, strength, 30 tablets per container, and distribution details. It includes dosage contents, storage instructions, an NDC number, and a barcode. Made in India.*

FDA Label Image

Package Label-principal Display Panel (10 mg/40 mg (30 Tablet Bottle))

Label for Amlodipine and Olmesartan Medoxomil Tablets, USP 10 mg/40 mg, film-coated oral tablets. The package contains 30 tablets. Distributed by Aurobindo Pharma USA, Inc., the label includes the NDC 65862-857-30 and indicates the product is made in India by Aurobindo Pharma Limited.*

FDA Label Image

Amlodipine Chemical Structure (Amlodipineolme Str1)

Chemical structure diagram showing the molecular structures of Amlodipine and Olmesartan Medoxomil, the active ingredients in the drug product. The structures depict the arrangement of atoms and functional groups characteristic to each molecule.*

FDA Label Image

Olmesartan Chemical Structure (Amlodipineolme Str2)

Chemical structure of Amlodipine and Olmesartan Medoxomil showing detailed molecular bonds and arrangements of both active ingredients.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.